Analysts expect that Aduro BioTech Inc (NASDAQ:ADRO) will announce earnings of ($0.36) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Aduro BioTech’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.30). Aduro BioTech reported earnings per share of ($0.44) during the same quarter last year, which suggests a positive year over year growth rate of 18.2%. The company is expected to issue its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Aduro BioTech will report full year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.22). For the next fiscal year, analysts forecast that the company will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Aduro BioTech.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The business had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the company posted ($0.54) earnings per share.

A number of equities analysts have recently issued reports on ADRO shares. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Aduro BioTech in a research note on Wednesday, September 27th. Oppenheimer set a $15.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research note on Monday, December 11th. Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Aduro BioTech presently has a consensus rating of “Buy” and an average target price of $17.71.

Aduro BioTech (NASDAQ ADRO) opened at $6.90 on Friday. The stock has a market capitalization of $533.40 and a P/E ratio of -5.07. Aduro BioTech has a one year low of $6.01 and a one year high of $14.05.

In other Aduro BioTech news, CEO Stephen T. Isaacs sold 16,400 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.96, for a total transaction of $130,544.00. Following the sale, the chief executive officer now owns 190,321 shares in the company, valued at approximately $1,514,955.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jennifer Lew sold 6,600 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $9.46, for a total value of $62,436.00. Following the sale, the vice president now owns 68,938 shares in the company, valued at approximately $652,153.48. The disclosure for this sale can be found here. Insiders sold a total of 267,714 shares of company stock valued at $2,251,452 over the last ninety days. 6.60% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in ADRO. Legal & General Group Plc grew its holdings in Aduro BioTech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Aduro BioTech during the 3rd quarter valued at $127,000. SG Americas Securities LLC acquired a new stake in Aduro BioTech during the 3rd quarter valued at $167,000. Trexquant Investment LP acquired a new stake in Aduro BioTech during the 3rd quarter valued at $175,000. Finally, Nisa Investment Advisors LLC grew its holdings in Aduro BioTech by 2,294.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 23,400 shares during the last quarter. Hedge funds and other institutional investors own 45.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aduro BioTech Inc (ADRO) Expected to Announce Earnings of -$0.36 Per Share” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/aduro-biotech-inc-adro-expected-to-announce-earnings-of-0-36-per-share/1813092.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Get a free copy of the Zacks research report on Aduro BioTech (ADRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.